| Style | Citing Format |
|---|---|
| MLA | Naser Moghadasi A. "Perspectives on the De-Escalation of Anti-Cd20 Monoclonal Antibodies in Patients With Multiple Sclerosis." Expert Opinion on Biological Therapy, vol. , no. , 2025, pp. -. |
| APA | Naser Moghadasi A (2025). Perspectives on the De-Escalation of Anti-Cd20 Monoclonal Antibodies in Patients With Multiple Sclerosis. Expert Opinion on Biological Therapy, (), -. |
| Chicago | Naser Moghadasi A. "Perspectives on the De-Escalation of Anti-Cd20 Monoclonal Antibodies in Patients With Multiple Sclerosis." Expert Opinion on Biological Therapy , no. (2025): -. |
| Harvard | Naser Moghadasi A (2025) 'Perspectives on the De-Escalation of Anti-Cd20 Monoclonal Antibodies in Patients With Multiple Sclerosis', Expert Opinion on Biological Therapy, (), pp. -. |
| Vancouver | Naser Moghadasi A. Perspectives on the De-Escalation of Anti-Cd20 Monoclonal Antibodies in Patients With Multiple Sclerosis. Expert Opinion on Biological Therapy. 2025;():-. |
| BibTex | @article{ author = {Naser Moghadasi A}, title = {Perspectives on the De-Escalation of Anti-Cd20 Monoclonal Antibodies in Patients With Multiple Sclerosis}, journal = {Expert Opinion on Biological Therapy}, volume = {}, number = {}, pages = {-}, year = {2025} } |
| RIS | TY - JOUR AU - Naser Moghadasi A TI - Perspectives on the De-Escalation of Anti-Cd20 Monoclonal Antibodies in Patients With Multiple Sclerosis JO - Expert Opinion on Biological Therapy VL - IS - SP - EP - PY - 2025 ER - |